Background: Coagulation factor II is proteolytically cleaved to form thrombin in the first step of the coagulation cascade which ultimately results in the stemming of blood loss. F2 also plays a role in maintaining vascular integrity during development and postnatal life. Mutations in F2 leads to various forms of thrombosis and dysprothrombinemia. Prothrombin is activated on the surface of a phospholipid membrane that binds the amino end of prothrombin and factors Va and Xa in Ca-dependent interactions; factor Xa removes the activation peptide and cleaves the remaining part into light and heavy chains. The activation process starts slowly because factor V itself has to be activated by the initial, small amounts of thrombin. & It is not known whether 1 or 2 smaller activation peptides, with additional cleavage after Arg-314, are released in natural blood clotting. & Thrombin can itself cleave the N-terminal fragment (fragment 1) of the prothrombin, prior to its activation by factor Xa. & The cleavage after Arg-198, observed in vitro, does not occur in plasma.
Description: Rabbit polyclonal to Thrombin II
Immunogen: KLH conjugated synthetic peptide derived from Thrombin II
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 70 kDa;
·Immunohistochemistry (Frozen/paraffin tissue section): 1/100-500;
·Immunocytochemistry: 1/100-500;
· ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
